Assembly Biosciences, Inc. (NASDAQ:ASMB)
| Market Cap | 441.73M-12.6% |
| Revenue (ttm) | 74.84M+125.1% |
| Net Income | -42.00K+99.9% |
| EPS | 0.00+109.6% |
| Shares Out | 19.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,751 |
| Open | 22.78 |
| Previous Close | 22.95 |
| Day's Range | 22.08 - 22.78 |
| 52-Week Range | 21.80 - 39.71 |
| Beta | 1.16 |
| Analysts | Buy |
| Price Target | 51.67(+131.81%) |
| Earnings Date | Nov 9, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About ASMB
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ASMB stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ASMB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ASMB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ASMB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ASMB Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Collaboration revenue from a related party | $13.37M | 68.02% |
| Less: | $6.29M | 31.98% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ASMB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ASMB from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ASMB
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $13.90M |
| IWMiShares Russell 2000 ETF | $7.93M |
| XBIState Street SPDR S&P Biotech ETF | $7.01M |
| VXFVanguard Extended Market ETF | $4.44M |
| VTWOVanguard Russell 2000 ETF | $1.90M |
| VHTVanguard Health Care ETF | $1.12M |
Estimated from each fund’s disclosed top holdings × AUM
ASMB Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ASMB’s recent data — informational, not investment advice